Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 364 participants.
Also called NCT03132519
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 364 participants
- Sponsor
- Fundacion Clinica Valle del Lili
- Registry
-
NCT03132519
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Colombia
- Registry status
- Completed
Technical summary
Registry record NCT03132519. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation
- Acronym
- REX
- Condition
- Cough
- Condition
- Hypertension
- Intervention (Drug)
- Remifentanil
- Lead sponsor
- Fundacion Clinica Valle del Lili
Record details
- Record id
cardio:ct-nct03132519- Content hash
b010d7ad3eb3c15e9de2ec3fd484874810db216871a1d5693863e8a8de354a20